EUVIMEDEUVIMED entdecken
Beobachtungsstudie

NeuroEPO plus (NeuralCIM ® ) in Alzheimer's disease: Post-trial observational follow-up study

Saily Sosa Pérez, Nelky Urrutia Amable, Carmen Elena Viada González, Patricia Lorenzo-Luaces iD, Lizet Sánchez Valdés iD, Tania Crombet Ramos iD, Kalet León Monzón iD, Teresita de Jesús Rodríguez Obaya iD, Leslie Pérez Ruiz iD

Journal of Alzheimer’s Disease · 2025-12 · 108 (3) · 1422-1435

DOI: 10.1177/13872877251386885 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of Alzheimer’s Disease, online erschienen am 22.10.2025. Verfasst von Saily Sosa Pérez und 8 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Iván Portuondo, San Antonio de los Baños, Artemisa, Cuba. Hauptthemen laut MEDLINE: Alzheimer Disease, Erythropoietin. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: Center of Molecular Immunology, The Cuban Ministry of Public Health..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

NeuroEPO plus is a recombinant erythropoietin with a sialic acid content like that produced by astrocytes, lacking the hematopoietic activity of conventional erythropoietin.

Objective

To evaluate the efficacy and safety of treatment with neuroEPO plus.

Methods

It was a post-trial observational follow-up study with four groups, NE: subjects who continued treatment with neuroEPO plus after trial, PB-NE: subjects who received a placebo during the trial and then receive neuroEPO plus, NE-CTRL: subjects who received neuroEPO plus during the trial and then interrupted treatment and CTRL: subjects who were never treated. NeuroEPO plus was administrated three times a week nasally. The primary outcome was changed from baseline in the score on the11-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-Cog11) at 96 weeks. Secondary outcomes included Global Deterioration Scale, Montreal Cognitive Assessment, Neuropsychiatric Inventory, and Lawton Instrumental Activities of Daily Living Scale.

Results

The adjusted median change from baseline in the ADAS-Cog11 score at 96 weeks was −6.0 in NE group and 11.0 in the CTRL group (difference, 21.0; 95% confidence interval [CI], 14.6–27.4; p = 0.000), −1.0 in the PB-NE (difference, 15.4; 95% CI, 9.0–21.8; p = 0.000) and 4.0 in the NE-CTRL (difference, 8.3; 95% CI, 1.4–15.2; p = 0.011). The results for secondary outcomes showed statistically significant differences.

Conclusions

Subjects who continued or started treatment with neuroEPO plus stabilized or slowed down the progression of the disease. These results and the method of drug administration, make neuroEPO plus an attractive option to consider for Alzheimer's disease patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseErythropoietinHumansMaleFemaleFollow-Up StudiesAgedTreatment OutcomeAged, 80 and overNeuropsychological TestsDouble-Blind MethodMental Status and Dementia TestsActivities of Daily LivingMiddle Aged

Stichwörter der Autor:innen

Alzheimer's diseaseNeuralCIM®clinical trialneuroEPO plusneuroprotective

Substanzen

Erythropoietin

Autor:innen und Institutionen

  • Hospital Iván Portuondo, San Antonio de los Baños, Artemisa, Cuba.
  • Center of Molecular Immunology (CIM), Havana, Cuba.

ORCID-Profile: Patricia Lorenzo-Luaces, Lizet Sánchez Valdés, Tania Crombet Ramos, Kalet León Monzón, Teresita de Jesús Rodríguez Obaya, Leslie Pérez Ruiz

Förderung

  • Center of Molecular Immunology
  • The Cuban Ministry of Public Health.

Zitieren

APA

Sosa Pérez, S., Urrutia Amable, N., Viada González, C. E., Lorenzo-Luaces, P., Sánchez Valdés, L., Crombet Ramos, T., León Monzón, K., Rodríguez Obaya, T. J., & Pérez Ruiz, L. (2025). NeuroEPO plus (NeuralCIM ® ) in Alzheimer's disease: Post-trial observational follow-up study. Journal of Alzheimer’s Disease, 108(3), 1422-1435. https://doi.org/10.1177/13872877251386885

Vancouver

Sosa Pérez S, Urrutia Amable N, Viada González CE, Lorenzo-Luaces P, Sánchez Valdés L, Crombet Ramos T, et al. NeuroEPO plus (NeuralCIM ® ) in Alzheimer's disease: Post-trial observational follow-up study. Journal of Alzheimer’s Disease. 2025;108(3):1422-1435. doi:10.1177/13872877251386885

BibTeX
@article{SosaPrez2025,
  author = {Sosa Pérez, Saily and Urrutia Amable, Nelky and Viada González, Carmen Elena and Lorenzo-Luaces, Patricia and Sánchez Valdés, Lizet and Crombet Ramos, Tania and León Monzón, Kalet and Rodríguez Obaya, Teresita de Jesús and Pérez Ruiz, Leslie},
  title = {NeuroEPO plus (NeuralCIM ® ) in Alzheimer's disease: Post-trial observational follow-up study},
  journal = {Journal of Alzheimer’s Disease},
  year = {2025},
  volume = {108},
  number = {3},
  pages = {1422--1435},
  doi = {10.1177/13872877251386885}
}
Kostenlos starten →